This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
by Zacks Equity Research
Thermo Fisher's (TMO) Amplitude Solution is likely to allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce.
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
by Zacks Equity Research
In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.
Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance
by Zacks Equity Research
Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.
4 Critical Care Device Stocks to Deflect the COVID-19 Curveball
by Debanjana Dey
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
New Strong Buy Stocks for April 8th
by Zacks Equity Research
MDC, NTR, LMAT, CSTR, and MYRG have been added to the Zacks Rank #1 (Strong Buy) List on April 8, 2021.
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
LeMaitre (LMAT) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
LeMaitre (LMAT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up
by Zacks Equity Research
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.
Zacks.com featured highlights include: Winnebago, Shutterstock, Ituran Location and Control, LeMaitre Vascular and Logitech
by Zacks Equity Research
Zacks.com featured highlights include: Winnebago, Shutterstock, Ituran Location and Control, LeMaitre Vascular and Logitech
5 Top-Ranked Liquid Stocks To Bet On For Alluring Returns
by Radhika Pujara
Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.
Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
by Zacks Equity Research
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
Zacks.com featured highlights include: Shutterstock, Winnebago Industries, LeMaitre and Logitech
by Zacks Equity Research
Zacks.com featured highlights include: Shutterstock, Winnebago Industries, LeMaitre and Logitech
4 Promising Top-Ranked Liquid Stocks to Boost Your Portfolio
by Radhika Pujara
Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.
3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)
by Zacks Equity Research
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.
Boston Scientific (BSX) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: LeMaitre Vascular
by Zacks Equity Research
LeMaitre Vascular is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
LeMaitre Vascular (LMAT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 440.00% and 59.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LeMaitre Vascular (LMAT) Q2 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
LeMaitre Vascular (LMAT) Meets Q1 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -2.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?